CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH METASTATIC KRAS-MUTANT LUNG ADENOCARCINOMAS.

Mutations in the KRAS gene are the most common driver oncogenes present in lung adenocarcinomas. We analyzed the largest multi-institutional database available containing patients with metastatic KRAS mutant lung adenocarcinomas.

In the LCMC study, 27% of lung adenocarcinomas patients harbored a KRAS mutation and up to third of them had another oncogenic driver. Patients with both KRAS and STK11 mutations had a significantly inferior clinical outcome.

https://www.jto.org/article/S1556-0864(19)30097-8/pdf